Clinical Trial Detail

NCT ID NCT01974440
Title A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

follicular lymphoma

marginal zone B-cell lymphoma

Therapies

Ibrutinib

Bendamustine + Rituximab

Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate

Age Groups: adult

No variant requirements are available.